Phoenix, AZNCT06931821Now EnrollingIRB Ready

Sustained Monomorphic VT (MMVT) Clinical Trial in Phoenix, AZ

Access cutting-edge sustained monomorphic vt (mmvt) treatment through this clinical trial at a research site in Phoenix. Study-provided care at no cost to qualified participants.

Sponsored by University of Arizona

Quick Self-Assessment

See if you qualify for this Phoenix location

Preparing your pre-screening questions…

Expert Care in Phoenix

Access sustained monomorphic vt (mmvt) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related sustained monomorphic vt (mmvt) treatment provided free

Apply for This Phoenix Location

Check if you qualify for this sustained monomorphic vt (mmvt) clinical trial in Phoenix, AZ

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Phoenix

    Convenient for AZ residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Phoenix site if eligible
  4. 4Begin participation

About This Sustained Monomorphic VT (MMVT) Study in Phoenix

This is a multicenter, prospective, parallel, randomized controlled trial to test for non-inferiority with an ILAM-guided VT ablation compared to conventional voltage- based ablation. The study has two treatment arms: conventional voltage mapping and ablation (control arm). In the investigational arm, the ablation strategy is guided by ILAM to target deceleration zones, blinded to voltage mapping. In the control arm, ablation will be performed to extensively ablate all low voltage regions (\<1.5mV) during sinus rhythm, right ventricular (RV) pacing, or left ventricular (LV) pacing, with discretionary use of pacemapping and activation mapping. In both arms, mapping with be performed with a multielectrode catheter (HD Grid) and ablation will be performed using an irrigated tip catheter (FlexAbility SE or Tactiflex catheters). In the control armonly voltage mapping displays will be utilized (blinded to functional ILAM and fractionation). High density mapping with automated last deflection annotation (Ensite X) will be performed in all patients randomized to ILAM approach during either sinus rhythm or RV pacing.

Sponsor: University of Arizona

Who Can Participate

Inclusion Criteria

Patient is ≥18 years of age.
Able and willing to comply with all study requirements.
At least one documented episode of sustained MMVT (\>30 sec) by either EGM or ECG (including Holter, or loop recorder) in the 6 months prior to enrollment.
Informed of the nature of the study, agreed to its provisions, and has provided written informed consent as approved by the Institutional Review Board/Ethics Committee (IRB/EC) of the respective clinical study site.
Refractory (i.e., not effective, not tolerated, or not desired) to at least one anti-arrhythmic medication (including, but not limited to beta blocker, mexiletine, amiodarone or sotalol) for treatment of MMVT.
Structural heart disease (ischemic or non-ischemic) with one of the following (a, b or c):
Evidence of myocardial scar by echocardiography (segmental wall motion or wall thinning), CT (wall thinning) and/or MRI (presence of delayed enhancement /late gadolinium enhancement) . CT or MRI with scar is mandatory for inclusion of NICM., or
Left ventricular ejection fraction (EF) \<50% \[documented within the last 6 months via transthoracic echocardiogram (TTE), MRI\] with presence of scar, or
Arrhythmogenic RV cardiomyopathy/dysplasia (per 2010 ARVC/D Task Force Criteria)

Exclusion Criteria

Subjects who meet any of the following exclusion criteria must be excluded from the clinical investigation:
Active infection (positive blood culture).
Patient is pregnant or nursing.
Cardiac surgery via sternotomy (CABG or valve repair/replacement) within 30 days prior to enrollment.
Contraindication to systemic anticoagulation (i.e., heparin, warfarin, or a direct thrombin inhibitor).
Currently receiving support via extracorporeal membrane oxygenation (ECMO) or ventricular assist device (VAD).
Left Ventriclar ejection fraction \< 15%.
Stroke within 30 days or presence of LV thrombus within 1 month prior to enrollment.
Idiopathic VT or preprocedural imaging without scar (MRI or CT).
Limited life expectancy of 1 year or less.
Presence of mitral and aortic valves both mechanical.
Ventricular tachycardia secondary to electrolyte imbalance or any other reversible or non-cardiac cause.
Severe aortic stenosis or flail mitral valve with severed mitral regurgitation.
Thrombocytopenia (defined as platelet count \<50,000/μl ) or coagulopathy.
Ventricular arrhythmias secondary to underlying channelopathies (LQTS, Brugada Syndrome).
Enrolled in an investigational study evaluating another device or drug that would confound the results of this study.
Other anatomic or co-morbid conditions that, in the investigator's opinion, could limit the patient's ability to participate in the study or to comply with follow up requirement of 1 year, or impact the scientific integrity of the study results.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Phoenix?

Yes, this clinical trial (NCT06931821) has an active research site in Phoenix, AZ that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Sustained Monomorphic VT (MMVT) Treatment Options in Phoenix, AZ

If you're searching for sustained monomorphic vt (mmvt) treatment options in Phoenix, AZ, this clinical trial (NCT06931821) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Phoenix research site is actively enrolling participants for this clinical trial. You'll receive care from experienced sustained monomorphic vt (mmvt) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all sustained monomorphic vt (mmvt) clinical trials near you to find additional studies recruiting in your area.

More Multiple Myeloma Trials in Phoenix, AZ

See all multiple myeloma clinical trials recruiting in Phoenix — not just this study.

Browse Multiple Myeloma Trials in Phoenix →

Ready to Join in Phoenix?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Phoenix, AZ